Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 17 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 6 days ago
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.

Dementia, Alzheimer’s disease tied to seizure risk

Audrey Abella
31 Jul 2019

The odds of experiencing seizures and epileptic seizure recurrence were higher among individuals with vs without dementia or Alzheimer’s disease (AD), according to data presented at AAIC 2019.

The risk of seizure disorders among individuals with and without dementia were evaluated using a large US national managed care database comprising >2.8 million individuals aged ≥60 years. Of these, 79,561 had a dementia diagnosis (56 percent female). [AAIC 2019, abstract P2-311]

Compared with those without dementia, individuals diagnosed with dementia had an increased risk of partial, generalized, and undifferentiated seizures (1.33 percent vs 0.22 percent, 2.83 percent vs 0.59 percent, and 5.13 percent vs 0.79 percent, respectively; p≤0.0001 for all). An increased risk of partial, generalized, and undifferentiated epilepsy was also observed among individuals with vs without dementia (0.56 percent vs 0.12 percent, 1.81 percent vs 0.35 percent, and 0.68 percent vs 0.14 percent, respectively; p≤0.0001 for all).

Overall, the presence of dementia signalled a higher risk of seizure disorders (hazard ratio [HR], 6.5, 95 percent confidence interval [CI], 4.4–9.5) and epilepsy (HR, 5.0, 95 percent CI, 4.8–5.2), which could be due to dementia medications, other conditions tied to seizures and dementia, or a combination of factors, said study author Dr Ruby Castilla-Puentes from the University of Cincinnati in Cincinnati, Ohio, US.

The findings underscore the importance of awareness and monitoring for seizures in individuals with dementia to ensure that they receive the appropriate treatment, added Castilla-Puentes, who called for further research to validate the findings.

Another analysis using data from a large prospective database (n=20,745) found that compared with individuals without AD, those with AD had a higher prevalence of active seizures (1.51 percent vs 0.35 percent, odds ratio [OR], 4.34, 95 percent CI, 3.01–6.27; p<0.0001) and were twice as likely to have had a previous seizure (3.14 percent vs 1.57 percent, OR, 2.03, 95 percent CI, 1.67–2.46; p<0.0001). [AAIC 2019, abstract P2-297]

The prevalence of active seizures increased with the duration of AD, rising from 1.51 percent at 4.8 years to 5.43 percent at 11 years (OR, 1.55, 95 percent CI, 1.39–1.73; p<0.0001).

Seventy percent of individuals with AD who experienced a seizure had a second seizure within 7.5 months.

After adjusting for age and disease duration, seizures in individuals with vs without AD were also linked to poor cognitive course (mean MMSE* score, 16.6 vs 19.6) and reduced functional performance (mean CDR-SB** score, 9.3 vs 6.8; p<0.0001), translating to more severe memory problems and impaired everyday life skills, respectively.

“[Our findings show that individuals] with AD are at increased risk for seizures, in particular in the more advanced stages of the disease, [with] an exceptionally high recurrence risk,” said study author Dr Jonathan Vöglein from the Ludwig-Maximilians-Universität München in Munich, Germany. “The high recurrence risk and potentially negative consequences of seizures suggest that individuals with AD should be treated with anti-epileptic drugs after their first seizure.”

These findings underline the need for seizure history assessment among individuals with AD to inform individual therapeutic decisions, as well as the need for systematic treatment studies of AD-associated epilepsy, added Vöglein. “It’s clearly important to focus on seizures in individuals with AD so that their treatment may be improved. This includes development of anti-epileptic drugs specifically for prevention of seizures in persons living with AD.”

“While we continue our push to find treatments and preventions for AD and other dementias, doctors should be aware of how common seizures are in this population to better monitor and treat these individuals,” commented Dr Maria Carrillo, chief science officer of the Alzheimer’s Association. Management of seizures and cognitive decline may be addressed through further research evaluating the shared mechanisms between AD and epilepsy to elucidate the impact of seizures on the brain, she added.

 


 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 17 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 6 days ago
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.